57 0 obj
VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California
Fully manage a net $1.5 billion portfolio of in-line business (Nasonex and Levitra) as well as pipeline products.
11760 articles from Category:WikiProject Pharmacology articles (13,371) Updated: 15:01, 28 April 2019 (UTC) by DePiep %PDF-1.4 %���� Before entering the life sciences industry, Dr Roblin practiced medicine for five years.Steve Conafay has 35 years of leadership and management experience in government relations, public policy and communications. From 2011 to 2013, he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories.
druganalyst ltd 172 tottenham court rd london w1t 7ns +44 20 3696 7500. log in Mr. Samant presently serves as a member of the board of directors of AmpliPhi Biosciences Corporation.
Ciara has a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotechnology industry.
While leader of the bio-life science practice at Fabiani & Company, he oversaw more than $810 million in non-dilutive financing awarded to the team’s clients.
Finney held this position through the successful $71 billion acquisition of Allergan by Actavis in March 2015. After the acquisition of Rempex Pharmaceuticals 2014, he led the commercial team that launched Vabomere™, Orbactiv® and Minocin IV.Prior to joining The Medicines Company Mike spent 25 years at Hoffmann La Roche in various functions spanning sales and marketing.
xref 2 position of executive vice president of strategic and legislative affairs. He received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT) under Nobel-laureate Professor K. Barry Sharpless.
Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. Bristol-Myers Squibb, Princeton, NJ. 1. He has developed 12 drugs approved world-wide in important diseases, including HIV, HCV, CMV, and tuberculosis.Mike McGuire joined Melinta Therapeutics in January of 2018 through the acquisition of the Medicines Company antibiotic franchise. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Prior to this, Dr. Perros worked for AstraZeneca AB as Vice President and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015.
But, as described here, Bristol Myers Squibb is committed to pursuing such clinical
Having maintained a life-long interest in infectious diseases, he has focused on researching and developing innovative human monoclonal antibodies and vaccines designed to address life-threatening infections.
Ramani holds a B.Sc.
Data from a Phase 2 trial expected in 2Q 2018. The susceptibility ranges in Europe and the rest of the world are 90%–100% for imipenem, 9%–70% for cefepime and 26%–72% for piperacillin/tazobactam.
54 7
Cellulose derivatives have an irreplaceable role as pharmaceutical excipients with a wide use in the pharmaceutical industry, including manufacturing of current medicines and development of new dosage forms (DF) and modern pharmaceutical manufaturing processes. Dr. Russo directly oversaw investigator-initiated research for a broad portfolio of anti-infectives, including daptomycin, fidaxomicin, ceftolozane/tazobactam, and tedizolid. John earned his B.S.B.A. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh was appointed President in June 2014 and served as Chief Medical Officer and Chairman of the Board of Directors from June 2012 to June 2014. Previously, Dr. Kennedy held several positions in the Program and Alliance department of Biogen Idec, managing projects spanning the drug discovery and development continuum. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Dr Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. Prior to Arsanis, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals (Cubist).
In 2004, she became a member of the inaugural class of the Rady School of Management at University of California, San Diego.
They were there for an educational program about what steps to take post-surgery to help prevent a recurrence. He served as senior vice president of corporate affairs for Glaxo Inc., where he was also a member of the Board of Directors.
from Stonehill College.Frank Pasqualone joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with the spin-off from Theravance, Inc. Hien M. Nguyen, Kileen L. Shier, Christopher J. Graber, Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae, Traditionally, physicians have not used cefepime (a fourth-generation cephalosporin with greater stability against β-lactamases) or β-lactam/β-lactamase inhibitors (BLBLIs) for infections caused by bacteria (generally Infections caused by extended-spectrum β-lactamases (ESBLs) that are generally produced by group 1 Enterobacteriaceae (e.g. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.